Achievelifesciences
Late-stage pharma developing cytisinicline, an investigational non-nicotine treatment for adults trying to quit smoking or vaping
Highlights
- New on EvolcAdded 2026-11-14
Recent signals
What changed at Achievelifesciences in the last 6 months, newest first. Each line links to its public source.
- 9 Nov 2026 In the news · Achieve Life Sciences changed its name to AchieveRx and ticker to QUIT achieverx.com
- 4 Nov 2026 Leadership hire · Hiring Executive Director, HCP Marketing achievelifesciences.bamboohr.com
- 30 Oct 2026 Leadership hire · Hiring Senior Director, Commercial Finance achievelifesciences.bamboohr.com
About Achievelifesciences
AchieveRx, The Quit Company, is a late-stage pharmaceutical company developing cytisinicline, an investigational compound that binds to nicotinic receptors, including the α4β2 receptor most closely linked to nicotine dependence. Cytisinicline contains no nicotine. It is not approved by the FDA and is not yet available for use.
The company's clinical program covers smoking cessation and vaping cessation. Its ORCA trials were conducted in the U.S. and enrolled adults who smoke or vape and want to quit, including people who had tried other treatments. The vaping program holds FDA Breakthrough Therapy designation and a Commissioner's National Priority Voucher.
The company was formerly known as Achieve Life Sciences and was renamed AchieveRx, The Quit Company, with its shares to trade under the ticker QUIT. Andrew D. Goldberg, MD, was appointed Chief Executive Officer in April 2026. Open roles are concentrated in U.S. commercial, medical, quality and finance functions.
Product: Cytisinicline, an investigational nicotinic receptor treatment in late-stage trials for smoking cessation and vaping cessation; not FDA-approved.
Jobs at Achievelifesciences
Open roles at Achievelifesciences in the Americas (2)
United States 2. From Achievelifesciences's careers page or applicant tracking system; each role links to the employer.
- Executive Director, HCP Marketing · United States
- Senior Director, Commercial Finance · United States
More biotech & pharma companies
Achira
Atomistic foundation simulation models for drug discovery and other physical-science applicationsNew on EvolcAdaptive Biotechnologies
Immune-receptor sequencing and data products for clinicians and biopharmaceutical companies developing and testing therapiesNew on EvolcAditum Bio
Biotech venture and operating firm that forms companies to develop drug candidates into medicines for patientsNew on EvolcAgcbio
Contract development and manufacturing services for biopharmaceutical companies developing biologics and advanced therapiesNew on EvolcAION Biosciences
Bioelectricity tools and medical devices for individuals seeking greater control over their biologyNew on EvolcAlltrna
Engineered tRNA medicines for patients with genetic diseases caused by disrupted protein productionNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Forms
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- BambooHRMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
